				•			02 patients with	·						
Patient	Gender	Age (vears)	Cyst size (cm)	Ductal dilatation	Mural nodule	Malignant cytopathology*	KRAS mutation (MAF)	GNAS mutation (MAF)	<i>VHL</i> alteration	CTNNB1 alteration (MAF)	<i>TP53</i> alteration (MAF)	PIK3CA mutation (MAF)	<i>PTEN</i> deletion (MAF)	Diagnosis
	Female	(years) 77	4.6	Absent	Present	Present	p.G12D (40%)	p.R201C (48%)	Absent	Absent	Homozygous deletion**	Absent	Homozygous deletion**	AdenoCA arising in an IPMN
2	Male	72	4.7	Absent	Present	Present	p.G12V (29%);	Absent	Absent	Absent	p.R175H (38%); p.G199L	p.H1047Y (28%)	Absent	AdenoCA arising in an IPMN
2							p.G12D (7%)				(18%)			_
3 <u>4</u>	Male Male	51 82	3.0 3.7	Present Present	Present Absent	Absent Absent	p.G12D (40%) p.G12D (19%)	p.R201C (53%) p.R201H (15%)	Absent Absent	Absent Absent	Homozygous deletion** p.R110L (16%)	Absent Absent	Absent Absent	AdenoCA arising in an IPMN AdenoCA arising in an IPMN
5	Male	61	5.2	Present	Present	Present	p.G12D (13%)	Absent	Absent	Absent	p.R175H (21%)	Absent	Absent	AdenoCA arising in an IPMN
6	Male	48	0.9	Absent	Present	Absent	p.G12V (15%)	Absent	Absent	Absent	p.R248W (16%)	Absent	Absent	AdenoCA arising in an IPMN
7	Male	46	3.7	Absent	Absent	Absent	p.G12V (33%)	Absent	Absent	Absent	Absent	p.E545K (29%)	Absent	AdenoCA arising in an IPMN
8	Female	62	2.7	Absent	Present	Absent	p.G12R (11%)	Absent	Absent	Absent	p.R273H (19%)	Absent	Absent	AdenoCA arising in an IPMN
9	Female	56	2.3	Absent	Absent	Absent	p.G12R (18%)	Absent	Absent	Absent	p.R273H (23%)	Absent	Absent	AdenoCA arising in an IPMN
10 11	Male Female	77 58	3.0 5.0	Absent Absent	Absent Absent	Absent Present	Absent p.G12V (7%)	p.R201H (51%) Absent	Absent Absent	Absent Absent	Absent Absent	p.E545K (50%) p.Y1021C (5%)	Absent Absent	AdenoCA arising in an IPMN AdenoCA arising in an IPMN
12	Female	72	2.0	Present	Absent	Absent	p.G12V (7%)	Absent	Absent	Absent	p.D259Y (43%)	Absent	Absent	AdenoCA arising in an IPMN
13	Male	74	2.7	Absent	Absent	Present	p.G12R (26%)	Absent	Absent	Absent	p.R273H (29%)	Absent	Absent	AdenoCA arising in an IPMN
14	Male	67	3.5	Present	Absent	Absent	Absent	p.R201C (30%)	Absent	Absent	p.R181C (34%)	Absent	Absent	IPMN with high-grade dysplasia
15	Male	72	1.5	Present	Absent	Absent	Absent	p.R201C (39%)	Absent	Absent	p.R248W (42%)	Absent	Absent	IPMN with high-grade dysplasia
16	Male	67	2.8	Present	Absent	Absent	p.G12R (45%)	p.R201C (92%)	Absent	Absent	Absent	Absent	Absent	IPMN with high-grade dysplasia
17 18	Male Female	72 34	3.0 11	Present Absent	Absent Absent	Present Absent	p.G12D (41%)	p.R201H (88%)	Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	IPMN with high-grade dysplasia MCN with high-grade dysplasia
19	Female	34 83	9.8	Absent	Absent	Absent	p.G12D (15%) p.G12R (22%)	Absent Absent	Absent Absent	Absent	Absent	Absent	Absent	MCN with high-grade dysplasia
20	Male	70	3.1	Present	Present	Absent	p.G12V (17%)	p.R201H (20%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
21	Male	73	3.0	Present	Absent	Absent	p.G13D (34%)	p.R201C (33%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
22	Male	67	4.2	Absent	Absent	Absent	p.Q61R (34%)	p.R201C (32%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
23	Female	59	2.3	Present	Absent	Absent	Absent	p.R201H (16%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
24	Male	45 76	1.3	Present	Absent	Absent	Absent	p.R201H (4%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
25 26	Male Female	76 63	4.3 3.5	Absent	Absent	Absent	Absent	p.R201H (25%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
26 27	Female Female	63 60	3.5 2.7	Absent Absent	Absent Absent	Absent Absent	p.G12D (42%) Absent	p.R201C (42%) p.R201H (27%)	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	IPMN with low-grade dysplasia IPMN with low-grade dysplasia
28	Male	77	2.5	Absent	Absent	Absent	p.G12D (25%)	Absent	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
29	Female	73	1.5	Absent	Absent	Absent	p.G12V (42%)	p.R201H (40%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
30	Female	70	6.5	Absent	Absent	Absent	p.G12R (34%)	Absent	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
31	Female	58	1.0	Present	Absent	Absent	Absent	p.R201H (7%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
32	Male	71	2.0	Absent	Absent	Absent	p.G12D (18%)	p.R201C (3%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
33 34	Female Male	70 57	3.0 1.2	Present Absent	Absent Absent	Absent Absent	p.G12V (47%) p.G12V (41%)	p.R201C (45%) p.R201H (42%)	Absent Absent	Absent Absent	Absent Absent	p.H1047R (3%) p.H1047R (3%)	Absent Absent	IPMN with low-grade dysplasia IPMN with low-grade dysplasia
35	Male	63	5.5	Present	Present	Absent	p.G12V (41%)	p.R2017 (42%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
36	Female	68	2.7	Present	Absent	Absent	p.G12R (43%)	p.R201C (44%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
37	Male	72	2.0	Present	Absent	Absent	p.G12V (10%)	p.R201H (12%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
38	Female	75	3.6	Absent	Absent	Absent	p.G13D (26%)	p.R201H (19%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
39	Male	72	1.0	Absent	Absent	Absent	p.Q61H (19%)	p.R201H (10%);	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
40		60	1.0				p.G12D (29%);	p.R201C (6%) p.R201H (21%);						100.401
40	Male	63	1.3	Absent	Absent	Absent	p.G12S (4%)	p.R201C (3%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
41	Female	78	5.3	Absent	Absent	Absent	p.G12D (13%)	Absent	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
42 42	Female	65 67	3.8 1.5	Absent	Absent	Absent	p.G12R (37%)	p.R201C (39%)	Absent	Absent	Absent	Absent	Absent	IPMN with low grade dysplasia
43 44	Male Male	63	3.4	Absent Absent	Absent Absent	Absent Absent	p.G12D (3%) Absent	Absent p.R201H (43%)	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	IPMN with low-grade dysplasia IPMN with low-grade dysplasia
45	Female	56	1.7	Absent	Absent	Absent	p.G12V (7%)	Absent	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
46	Male	68	3.1	Present	Absent	Absent	p.G12V (4%)	p.R201C (4%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
47	Male	75	3.0	Present	Absent	Absent	p.G12V (34%)	Absent	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
48	Male -	69	1.3	Absent	Absent	Absent	Absent	p.R201C (39%)	Absent	Absent	Absent	p.E542K (3%)	Absent	IPMN with low-grade dysplasia
49 50	Female	78 70	3.7	Absent	Absent	Absent	p.G12V (45%)	Absent	Absent	Absent	Absent	Absent	Absent	IPMN with low grade dysplasia
50 51	Male Male	79 59	3.1 1.4	Present Present	Absent Absent	Absent Absent	p.G12V (41%) Absent	p.R201H (40%) p.R201H (7%)	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	IPMN with low-grade dysplasia IPMN with low-grade dysplasia
52	Female	60	3.0	Absent	Absent	Absent	p.G12R (33%)	p.R201C (42%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
53	Female	70	2.5	Present	Absent	Absent	p.Q61L (49%)	p.R201C (46%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
54	Male	76	3.0	Present	Absent	Absent	p.G12D (17%)	p.R201H (5%);	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
55	Female	68	2.9	Absent	Absent	Absent	p.G12D (17%)	p.Q227H (3%) Absent	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
56	Male	71	4.0	Present	Absent	Absent	Absent	p.R201C (49%)	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
57	Female	56	1.7	Absent	Absent	Absent	p.G12V (7%)	Absent	Absent	Absent	Absent	Absent	Absent	IPMN with low-grade dysplasia
58	Male	76	2.9	Absent	Absent	Absent	p.G12V (34%)	Absent	Absent	p.T41A (40%)	Absent	Absent	Absent	IPMN with low-grade dysplasia
59	Female	62	4.8	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	T321fs*1 (11%)	MCN with low-grade dysplasia
60	Female	47	4.8	Absent	Present	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	MCN with low-grade dysplasia
61 62	Female Female	44 53	4.8 5.5	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	MCN with low-grade dysplasia MCN with low-grade dysplasia
62 63	Female Female	53 40	5.5 4.6	Absent Absent	Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent	Absent Absent	Absent	Absent Absent	MCN with low-grade dysplasia
64	Female	52	4.4	Absent	Absent	Absent	p.G12S (4%)	Absent	Absent	Absent	Absent	Absent	Absent	MCN with low-grade dysplasia
65	Female	48	6.5	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	MCN with low-grade dysplasia
66	Female	61	2.9	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	MCN with low-grade dysplasia
67	Female	65	6.2	Present	Absent	Absent	Absent	Absent	c.464-1G>C	Absent	Absent	Absent	Absent	Serous cystadenoma
68	Female	64	5.0	Present	Absent	Absent	Absent	Absent	p.L89R	Absent	Absent	Absent	Absent	Serous cystadenoma
69 70	Female	69 76	3.6 5.4	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Serous cystadenoma
70 71	Female Male	76 70	5.4 2.3	Present Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Absent Absent	Cystic PanNET Cystic PanNET
71 72	Female	70 52	1.0	Present	Absent	Present	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Cystic PanNET
73	Female	22	1.5	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Cystic PanNET
74	Male	58	1.6	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Cystic PanNET
	Male	59	2.4	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Cystic PanNET
75		45	2.7	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Cystic PanNET
75 76	Male							A bcont	Abcont	Absent	Absent	Absent	Absent	Cystic PanNET
76 77	Male	72 62	3.4	Absent	Absent	Absent	Absent	Absent	Absent					•
76 77 78	Male Male	62	1	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Cystic PanNET
76 77	Male													•

82	Female	35	6.8	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
83	Male	61	7.8	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
84	Female	54	1.5	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
85	Female	56	2.2	Absent	Present	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
86	Female	64	8.0	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
87	Male	56	6.0	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
88	Female	76	8.6	Present	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
89	Male	49	3.6	Absent	Present	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
90	Female	77	2.2	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
91	Male	69	2.1	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
92	Male	49	3.6	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
93	Female	34	4.2	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
94	Female	71	2.6	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
95	Female	62	7.0	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
96	Female	73	0.9	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Pseudocyst
97	Female	52	2.1	Absent	Absent	Present	Absent	Retention cyst						
98	Female	70	4.5	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Retention cyst
99	Male	48	4.2	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Lymphoepithelial cyst
100	Male	63	2.6	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Lymphoepithelial cyst
101	Male	73	2.1	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Epidermoid cyst
102	Female	55	2.2	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Absent	Squamoid cyst

Abbreviations: AdenoCA, adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm; MAF, mutant allele frequency; MCN, mucinous cystic neoplasm; PanNET, pancreatic neuroendocrine tumor

^{*}Malignant cytopathology was defined as either at least suspicous for adenocarcinoma.

^{**}Homozygous deletion is based on low sequencing coverage of amplicons for the gene of interest.